awards Archives - Sanford Burnham Prebys
Institute News

Brain cancer researcher Jia Zack Shen wins 2022 Eric Dudl scholarship

AuthorMiles Martin
Date

October 18, 2022

For the first time since the pandemic, Sanford Burnham Prebys presented the Eric Dudl Endowed Scholarship Award in person at last week’s Cancer Center Open House. This year’s recipient, selected by leaders at the Cancer Center, was Jia Zack Shen, PhD, a staff scientist in the lab of Charles Spruck, PhD The award pays tribute to Eric Dudl, a postdoctoral researcher who succumbed to cancer in 2006, when he was just 33.

Eric Dudl
Eric Dudl

“Eric was ill at such a young age, but he was also very lucky because he knew exactly what his dream job was and what his life meant,” says Shen. “Eric’s compassion and dedication to cancer research has been inspiring and encouraging for our postdocs here at Sanford Burnham Prebys. Thank you to the Dudl family for helping me continue my career here.”

Honoring Eric Dudl
In 2005, Eric Dudl had just begun his postdoctoral research in a cancer lab at Sanford Burnham Prebys, where he was known as kind, helpful and a fast learner. Then, at age 32, he was diagnosed with non-small cell lung cancer. This only fueled his fiery passion for cancer research.

“Even when he was very ill, Eric wanted to make a contribution in the time he had,” says Jim Dudl, MD, Eric’s father. “One day I looked at Eric and asked, ‘Why don’t you take some time off work? Get your energy back and go back in when you feel better?’ He looked up at me and said, ‘Why would I do that? This is the best job in the world!’”

Tragically, Eric Dudl would pass away in 2006, at age 33. The next year, his parents established the Eric Dudl Endowed Scholarship Fund to support young cancer researchers like their son.
“These talented scientists pick up where Eric had to leave off,” says Barbara Dudl, Eric’s mother.

“We are so grateful to the Institute for their compassion for Eric during his illness and helping us create this scholarship. The scientists who are now working on new discoveries might one day save the life of someone like Eric.”

The award presentation was emceed by Cosimo Commisso, PhD, and featured comments from Eric’s parents, as well as his brother, Bret.

“This scholarship fund is the best way we can honor Eric, because he was so passionate about education and supporting others,” says Bret. “The fact that he now helps other postdocs further their work to fight cancer is exactly what he would have wanted.”

Meet the recipient: Jia Zack Shen
Shen started at the Institute as a postdoctoral researcher in 2016, winning a Fishman Fund Award that year. He has since transitioned to a permanent role as a staff scientist, and the funding from this award will help continue to support his role.

“Sanford Burnham Prebys has a great, noncompetitive atmosphere, and the resources we have here are excellent,” says Shen. “Combining cancer research with the drug discovery capabilities we have at SBP is my dream.”

Shen’s research focuses on killing cancer stem cells by shutting off their ability to self-renew and by promoting a response from the immune system, delivering what Shen and his colleagues call a “one-two punch.” Shen has been working specifically on glioblastoma, one of the most aggressive brain cancers.

“Glioblastoma is one of the most devastating diseases, and there is a desperate need for better ways to treat it,” says Shen. “I am working hard to leverage the immune system to fight glioblastoma and save thousands of lives.”

Institute News

Prestigious Forbeck Scholar Award granted to Sanford Burnham Prebys cancer researcher

AuthorMonica May
Date

December 23, 2019

Breast cancer expert Brooke Emerling, PhD, an assistant professor at Sanford Burnham Prebys, has been named a Forbeck Scholar by the William Guy Forbeck Research Foundation. This prestigious award recognizes early-career cancer researchers for their achievements, research and dedication to the field. As an award winner, Emerling receives rare access to several three-day “think tank” events featuring the world’s top cancer clinicians and scientists.

“My goal is to create therapies that help more breast cancer patients survive cancer,” says Emerling. “The opportunity to discuss my ideas and research with the absolute leaders in my field is incredible and only accelerates my work toward that end.”

Emerling is working to find treatments for triple-negative breast cancer, which is treatable only with standard surgery, chemotherapy and radiation. The lack of specific treatments means that it has a mortality rate three times higher than the other types of breast cancer. Emerling is working to find a personalized medicine that blocks several proteins she identified that allow the triple-negative breast cancer to grow, called PI5P4Ks.

The William Guy Forbeck Research Foundation was established in 1985 by George and Jennifer Forbeck in honor of their son, who succumbed to a rare childhood cancer at age 11. Today the foundation promotes advances in cancer research through collaboration. The foundation began the Forbeck Scholar award as a way to recognize early-career cancer researchers with great future promise. Past Forbeck Scholar award winners hail from Dana-Farber Cancer Institute, the Broad Institute, Cold Spring Harbor Laboratory and other top-tier institutes.

Institute News

Sanford Burnham Prebys scientists win two American Cancer Society awards

AuthorMonica May
Date

October 1, 2019

Innovation and Collaboration of the Year Awards

The San Diego cancer community—including oncologists, oncology nurses, radiologists, cancer researchers and their friends and family—gathered on September 22 to celebrate progress made in reducing cancer deaths and recognize exceptional individuals and institutions at the inaugural American Cancer Society’s Celebration of Cancer Care Champions in San Diego.

More than 40 finalists were selected, including Sanford Burnham Prebys professors Robert Wechsler-Reya, PhD, who received the Innovation of the Year award for his team’s creation of a new model for studying a brain tumor that commonly arises in infants; and Jorge Moscat, PhD, and Maria Diaz-Meco, PhD, who received the Collaboration of the Year award for their partnership with clinicians at Scripps Clinic who uncovered a novel way to potentially identify a deadly form of colorectal cancer.

Nominations were reviewed by an independent review committee composed of representatives from 10 leading healthcare and research institutions, including Celgene, Kaiser Permanente, Rady Children’s Hospital, Scripps MD Anderson Cancer Center, Moores Cancer Center at UC San Diego Health and more. (Note: Members of the review committee did not score nominations for their own institutions.)

Read on to learn more about our award-winning research:

Innovation of the Year: A new model for studying brain tumors that strike infants
Robert Wechsler-Reya, PhD, a professor at Sanford Burnham Prebys and program director of the Joseph Clayes III Research Center for Neuro-Oncology and Genomics at the Rady Children’s Institute for Genomic Medicine, was honored for his development of a novel mouse model of a pediatric brain tumor called choroid plexus carcinoma. This tumor most commonly arises in infants under the age of one who are too young to undergo radiation treatment. Until now, drug development has been hindered by the lack of models that could help researchers better understand the cancer. Wechsler-Reya and his team have already used the model to identify potential drug compounds that may be therapeutically useful.

Collaboration of the Year (tie): Novel biomarkers to help detect a deadly colorectal cancer 
Sanford Burnham Prebys professors Jorge Moscat, PhD, and Maria Diaz-Meco, PhD; and Scripps Clinic clinicians Darren Sigal, MD, and Fei Baio, MD, were recognized for their successful collaboration. Together, the researchers revealed that loss of two genes drives the formation of the deadly serrated form of colorectal cancer—yielding promising biomarkers that could identify the tumor type. This insight could lead to the development of a diagnostic test to identify serrated colorectal cancer, a hurdle that previously limited our understanding of this deadly cancer type and the development of effective treatments. The research also identified a combination treatment that has treated the cancer in mice.

Institute News

Ze’ev Ronai wins Lifetime Achievement Award from the Society for Melanoma Research

AuthorJessica Moore
Date

November 10, 2016

Ze’ev Ronai, PhD, chief scientific advisor at Sanford Burnham Prebys Medical Research Institute (SBP) and professor in its NCI-designated Cancer Center, is the 2016 recipient of the Society for Melanoma Research’s Lifetime Achievement Award. The award honors “an individual who has made major and impactful contributions to melanoma research throughout their career.”

Ronai is being recognized for his significant contributions to melanoma research that are advancing understanding of this deadly form of skin cancer and could lead to new treatments. His studies on ultraviolet (UV) irradiation-induced changes that promote melanoma showed how they rewire signaling networks. A major discovery from those inquiries was that one player in that rewiring, a protein called ATF2, can switch from its usual tumor-preventive function to become a tumor promoter. Work by the Ronai lab also mapped how ATF2 contributes to melanoma development, and identified specific factors involved in melanoma response to therapy and metastatic potential.

In mapping the landscape of melanoma signaling, Ronai’s lab also uncovered the important role the enzyme PDK1 plays in melanoma development and metastasis. More recently, Ronai’s studies identified a mechanism underlying resistance of melanoma to BRAF inhibitor therapy, paving the road for a new clinical trial. Integral to Ronai’s research are translational initiatives, including the development of SBI-756, a small molecule that disrupts the complex that initiates protein synthesis and prevents melanoma resistance when combined with BRAF inhibition.

Ronai and his team also study how cancer cells thrive under harsh conditions, such as lack of oxygen or nutrients. That line of research has produced important insights into cancer heterogeneity and its capacity to drive the survival of the select few cancer cells that are resistant to therapy and able to metastasize. Ronai’s studies of proteins that control stress responses, such as Siah and RNF5, have furthered understanding of these processes and identified new targets for future therapies.

Ronai’s record of scientific accomplishments was recognized by the National Cancer Institute with an Outstanding Investigator Award, a seven-year grant that allows recipients to pursue projects of unusual potential. Ronai’s unique focus on how gene activity changes in cancer promises to continue establishing new paradigms for how cancers develop and respond to therapy.

About the Society for Melanoma Research

The Society for Melanoma Research (SMR) is an all-volunteer group of scientists dedicated to finding the mechanisms responsible for melanoma and, consequently, new therapies for this cancer. SMR contributes to advances in melanoma research by catalyzing collaborations among basic, translational, and clinical researchers, carrying new technology-based discoveries from bench to bedside and back.

About melanoma

The incidence of melanoma, the most lethal form of skin cancer, is rising at one of the fastest rates of all cancers in the U.S. Melanoma can strike people of all ages and is the most common form of cancer among young adults ages 25 to 29.

Institute News

Doug Lewandowski, PhD, elected as a Fellow of the American Association for the Advancement of Science

AuthorJessica Moore
Date

April 28, 2016

The director of Translational Cardiovascular Research at SBP’s Lake Nona campus was recently named a Fellow of the American Association for the Advancement of Science (AAAS). E. Douglas Lewandowski, PhD, was one of 33 scientists selected to become a AAAS fellow in the Section on Medical Sciences, recognizing his “distinguished contributions to fundamental aspects of cardiac metabolism and their implications for heart disease.” Continue reading “Doug Lewandowski, PhD, elected as a Fellow of the American Association for the Advancement of Science”

Institute News

Peter Crawford, MD, PhD, elected to the American Society for Clinical Investigation

Authorjmoore
Date

April 19, 2016

The director of SBP’s Cardiovascular Metabolism Program was recently elected into a pre-eminent honor society for physician-scientists. Peter Crawford, MD, PhD, was one of 74 medical researchers whose nominations to the American Society for Clinical Investigation (ASCI) were accepted in 2016. This distinction is conferred only on investigators who have made significant scientific advances prior to the age of 50. Continue reading “Peter Crawford, MD, PhD, elected to the American Society for Clinical Investigation”